In the cohort, 91.8.% of the patients had ductal carcinoma, 37.3% had de novo metastatic disease, 41.6% had HR + HER2-, 33.9% HER2-positive and 24.4% TNBC. This evidence concerns the gene ERBB2 and breast ductal adenocarcinoma.